HSBC Holdings
LGND icon

HSBC Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

HSBC Holdings’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,527
Closed -$219K – 3127
2019
Q3 		$219K Hold
3,527
– – ﹤0.01% 2817
2019
Q2 		$251K Buy
+3,527
New +$260K ﹤0.01% 2427

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HSBC Holdings's LGND Position: Q2 2026 in Review

HSBC Holdings reduced its Ligand Pharmaceuticals (LGND) stake by 29% in Q2 2026, selling an estimated $236K and leaving 2,455 shares worth $773K. The position accounts for ﹤0.01% of the portfolio, ranked #2074.

HSBC Holdings first reported a position in LGND in Q3 2014 and has held it in 37 quarters since. The position peaked at $7.87M in Q1 2019. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • HSBC Holdings held 2,455 shares of Ligand Pharmaceuticals worth $773K as of Q2 2026.
  • HSBC Holdings sold 1,000 Ligand Pharmaceuticals shares in Q2 2026, an estimated $236K.
  • Ligand Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2074 holding.
  • HSBC Holdings first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 37 quarters since.
  • HSBC Holdings's Ligand Pharmaceuticals position peaked at $7.87M in Q1 2019.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.